Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 26.51% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 26.51% decrease from a year earlier, with the FY2025 full-year figure at $2.2 billion, down 7.56% from the prior year.
• Total Non-Current Liabilities retreated to $1.7 billion in Q1 2026 per SRPT's latest filing, from $2.2 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $2.7 billion in Q4 2022 and bottomed at $1.7 billion in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $2.3 billion (2024), against an average of $2.3 billion.
• Across the five-year window, Total Non-Current Liabilities advanced 25.1% in 2022 and declined 26.51% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $2.7 billion in 2022, then declined by 12.54% to $2.4 billion in 2023, then gained by 0.88% to $2.4 billion in 2024, then fell by 7.56% to $2.2 billion in 2025, then fell by 24.25% to $1.7 billion in 2026.
• Per Business Quant, the three latest SRPT Total Non-Current Liabilities figures stand at $1.7 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.1 billion (Q3 2025).